CA-SYNTERACTHCR
10.11.2016 13:02:35 CET | Business Wire | Press release
Executives from SynteractHCR , a full-service, international contract research organization (CRO), are continuing to exhibit and speak at various industry conferences around the globe in November. The events include World Immunotherapy Congress, World Orphan Drug Congress Europe and Partnerships in Clinical Trials Europe. Each event brings together thought leaders from biotech, pharma and related industries to network and stay abreast of new developments and best practices.
The World Immunotherapy Congress , Nov. 14-16 at Congress Center in Basel, Switzerland, offers experts multiple opportunities to discuss the promising developments in immunotherapy, including immune checkpoint inhibitors and cell therapy. SynteractHCR will exhibit in booth #28 and will have clinical trial experts available to meet with companies that are focused on developing oncology and other therapeutic indication trials using immunotherapy techniques. To make an appointment to meet with SynteractHCR, contact Volker Knorz: Volker.Knorz@SynteractHCR.com .
The World Orphan Drug Congress Europe 2016 will be held Nov. 15-17 in Brussels, where Dr. Stephan de la Motte, chief medical advisor for SynteractHCR, will host two roundtables: the first on “Sharing Practical Insights on the Planning and Execution of Orphan Drug Clinical Trials ” at 11:30 am on Wed., Nov. 16th and the second on the same topic (time, date). Clients and others who might like to meet with the team at World Orphan may contact Alexandre Wallard: Alexandre.Wallard@SynteractHCR.com .
At the Partnerships in Clinical Trials Europe (PCT) event, Vice President for Global Medical and Regulatory Affairs Dr. Martine Dehlinger-Kremer will present : “Planning for the Impact of the New EU Clinical Trials Regulation and the Implications of the UK Brexit” from 11:25 a.m. – 12:00 p.m. EDT on Thursday, November 17th . Attendees will leave the presentation prepared for the upcoming EU Regulation and will better understand how Brexit may affect the new regulation. SynteractHCR will exhibit in booth #173.
Lastly, clinical trial experts from the company will also attend BVMA in Munich from Nov. 24-25th , 2016. Those who wish to meet with the team at either PCT or BVMA, or with Dr. Dehlinger-Kremer, may contact Xavier Morillon: Xavier.Morillon@SynteractHCR.com .
See SynteractHCR's full schedule of events and follow its social channels on LinkedIn and Twitter for live updates during all conferences.
About SynteractHCR
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision ” philosophy, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161110005548/en/
Contact:
SynteractHCR
Beth Walsh, 760-230-2424
Beth@clearpointagency.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global Announces New Long-Term LNG Partnership with Hanwha of Korea27.2.2026 01:00:00 CET | Press release
20-year sales and purchase agreement marks Venture Global’s first SPA with a Korean entity Today, Venture Global, Inc. (NYSE: VG) and Hanwha Aerospace Co., Ltd. announced the execution of a new Sales and Purchase Agreement (SPA) for the purchase of 1.5 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for twenty years starting in 2030. This agreement brings Venture Global’s long-term contracted portfolio to over 46 MTPA. “Venture Global is thrilled to announce our first long-term supply deal in Korea through a new partnership with Hanwha Aerospace which marks another important step in expanding reliable, long-term LNG supply to our partners in Asia,” said Mike Sabel, CEO of Venture Global. “We are proud to support growing global energy needs with low-cost, secure American LNG while strengthening the strategic energy partnership between the United States and South Korea to support long-term industrial and economic growth.” About Venture Global Ventu
Hydnum Steel Secures 500 MW of Electrical Power, a Key Step Forward in the Construction of Its Clean Steel Plant in Spain27.2.2026 00:00:00 CET | Press release
The company will produce flat steel, a product for which the EU has an annual deficit of almost 11 million tons Hydnum Steel has taken a decisive step towards constructing Spain’s first clean steel plant after being granted access to the electricity grid at the Brazatortas node in the province of Ciudad Real. The company has been granted an electricity capacity of 500 MW, as published in the Official State Gazette, which should be enough to guarantee supply to its electric arc furnace. This concession marks a significant milestone for a pioneering project in the Iberian Peninsula. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225309290/en/ Image recreating the steel plant that Hydnum Steel will build in Puertollano, Spain Hydnum Steel is consolidating its position as a reliable supplier of clean European steel. The fully digitally integrated plant will produce hot-rolled steel coils efficiently and sustainably, with bene
1089 Inc. Partners with Price Forbes and Oka-Lloyd's Syndicate 1922 to Launch Market-Defining First: Carbon Asset Insurance Framework for Transportation and Energy Sectors26.2.2026 23:01:00 CET | Press release
New program introduces dedicated insurance safeguards and immutable transfer infrastructure to advance fiscal maturation of global carbon markets, enabling scaled participation across world's highest-emitting sectors, Transportation and Energy. 1089 Inc., in collaboration with Price Forbes and Oka, The Carbon Insurance Company, announce launch of an insured carbon asset designed to bring institutional safeguards, disciplined financial architecture, and verifiable data integrity to carbon markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226012782/en/ 1089 Inc. is Advancing Carbon™, focused on evolving global carbon markets and decarbonizing the highest-emitting sectors on the planet: Transportation and Energy. The framework provides defined risk coverage for 1089’s CX89 Advanced Fuels Carbon Assets, underwritten by Lloyd’s Syndicate 1922 and placed with the support of Price Forbes and Oka. The program introduces ins
Sun Nuclear QADS 2026 Event Combines Clinical Insight and New Innovations for Advancing Radiation Therapy QA26.2.2026 23:00:00 CET | Press release
15th QA & Dosimetry Symposium convenes medical physics and radiation therapy community in RomeTwo days of sessions span diverse topics from 24 clinical practitioners and thought leadersEvent introduces new Daily QA™ 4 Pro device and features expansion of AI-enabled solutions Sun Nuclear, a Mirion Medical company, today opened the QA & Dosimetry Symposium (QADS), taking place over the next two days in Rome, Italy. The 15th installment brings together more than 230 clinical physicists and radiation medicine professionals from nearly 40 countries. Participants from diverse clinical environments will earn continuing education credits while sharing practical insights, emerging approaches, and real-world experiences shaping the future of quality and patient safety in cancer care. Building on its legacy as a peer-driven forum with practical applications, QADS 2026 features sessions delivered by 24 speakers spanning: Future Directions in Machine and Patient QA and In-vivo Dosimetry Stereotacti
Lattice to Highlight Low Power, Edge-Ready Programmable Solutions at embedded world 202626.2.2026 22:00:00 CET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced its exhibition plan for embedded world 2026, where it will demonstrate how its low power, small form factor FPGA innovations help engineers accelerate intelligent, scalable designs from cloud to sensor. At the event, Lattice will participate in expert panel discussions, lead conference sessions, and host an interactive booth experience filled with real-world solutions for the Automotive, Industrial, and Security markets from Lattice and its innovation partners. Who: Lattice Semiconductor What / When: Lattice Booth and Demo Showcase: March 10 – 12, Hall 4, Booth #528 Expert Panel featuring Lattice Chief Strategy and Marketing Officer Esam Elashmawi March 10 at 1:30 p.m. GMT+1, Hall 3, Booth #611 Conference Sessions March 10 at 5 p.m. GMT+1 Safety & Security: “Trusted Resilience Edge – Unified FPGA-TPM for Post-Quantum Cryptography RED & Cyber Resilience Act” March 11 at 10:30 a.m. GMT+1 IoT & Connec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom